Related Experiment Video
Updated: Jul 26, 2026
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
Published on: January 25, 2015
Treatment of primary liver cancer
L Hafström1, P Naredi, P Lindnér
1Department of Surgery, Umeå University Hospital, Sweden.
Objective:
To evaluate treatment of patients with primary liver cancer.
Design:
Prospective protocol including subsets of randomised studies.
Setting:
University hospital, Sweden.
Subjects:
123 patients with primary liver cancer.
Interventions:
64 patients underwent hepatic resection, 25 were included in a trial of adjuvant chemotherapy. 24 further patients whose tumours were not resectable were included in a trial of intra-arterial infusion of doxorubicin.
Main Outcome Measures:
Survival and postoperative morbidity.
Results:
The median survival time for patients who had had resections was 11 months (range 0-111). Twelve per cent survived more than 5 years. No prognostic factor had any significant effect on outcome. The postoperative mortality was 11% (7/64). The patients allocated to adjuvant chemotherapy survived a median of 10 months (range 1-47) and the controls 29 months (range 8-111) (p=0.04). Patients with unresectable liver cancer treated with intra-arterial doxorubicin lived no longer than untreated controls (median 8 months (range 1-56) compared with 7 months (range 1-28)).
Conclusions:
Treatment of patients with primary liver cancer is still an unsolved problem. Adjuvant chemotherapy with doxorubicin had no beneficial effect on survival.
